Ligand Pharmaceuticals Statistics
Total Valuation
CBOAF has a market cap or net worth of 692.11 million. The enterprise value is 857.66 million.
| Market Cap | 692.11M |
| Enterprise Value | 857.66M |
Important Dates
The next estimated earnings date is Friday, August 22, 2025.
| Earnings Date | Aug 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 418.94M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +10.71% |
| Shares Change (QoQ) | -17.75% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 278.06M |
Valuation Ratios
The trailing PE ratio is 52.53 and the forward PE ratio is 25.21.
| PE Ratio | 52.53 |
| Forward PE | 25.21 |
| PS Ratio | 4.67 |
| PB Ratio | 3.53 |
| P/TBV Ratio | 3.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 18.02 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.47, with an EV/FCF ratio of -57.38.
| EV / Earnings | 65.10 |
| EV / Sales | 5.55 |
| EV / EBITDA | 18.47 |
| EV / EBIT | 27.92 |
| EV / FCF | -57.38 |
Financial Position
The company has a current ratio of 1.61, with a Debt / Equity ratio of 0.84.
| Current Ratio | 1.61 |
| Quick Ratio | 0.39 |
| Debt / Equity | 0.84 |
| Debt / EBITDA | 3.71 |
| Debt / FCF | -11.07 |
| Interest Coverage | 4.40 |
Financial Efficiency
Return on equity (ROE) is 7.32% and return on invested capital (ROIC) is 5.59%.
| Return on Equity (ROE) | 7.32% |
| Return on Assets (ROA) | 4.41% |
| Return on Invested Capital (ROIC) | 5.59% |
| Return on Capital Employed (ROCE) | 7.24% |
| Revenue Per Employee | 1.47M |
| Profits Per Employee | 130,449 |
| Employee Count | 101 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 1.61 |
Taxes
In the past 12 months, CBOAF has paid 8.85 million in taxes.
| Income Tax | 8.85M |
| Effective Tax Rate | 40.17% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 94.39 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CBOAF had revenue of 148.19 million and earned 13.18 million in profits. Earnings per share was 0.03.
| Revenue | 148.19M |
| Gross Profit | 58.69M |
| Operating Income | 29.45M |
| Pretax Income | 22.02M |
| Net Income | 13.18M |
| EBITDA | 44.01M |
| EBIT | 29.45M |
| Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 6.63 million in cash and 165.39 million in debt, giving a net cash position of -158.76 million.
| Cash & Cash Equivalents | 6.63M |
| Total Debt | 165.39M |
| Net Cash | -158.76M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 195.94M |
| Book Value Per Share | 0.47 |
| Working Capital | 28.80M |
Cash Flow
In the last 12 months, operating cash flow was 38.40 million and capital expenditures -53.35 million, giving a free cash flow of -14.95 million.
| Operating Cash Flow | 38.40M |
| Capital Expenditures | -53.35M |
| Free Cash Flow | -14.95M |
| FCF Per Share | n/a |
Margins
Gross margin is 39.60%, with operating and profit margins of 19.88% and 8.89%.
| Gross Margin | 39.60% |
| Operating Margin | 19.88% |
| Pretax Margin | 14.86% |
| Profit Margin | 8.89% |
| EBITDA Margin | 29.70% |
| EBIT Margin | 19.88% |
| FCF Margin | n/a |
Dividends & Yields
CBOAF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 56.68% |
| Buyback Yield | -10.71% |
| Shareholder Yield | n/a |
| Earnings Yield | 1.90% |
| FCF Yield | -2.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CBOAF has an Altman Z-Score of 1.72 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.72 |
| Piotroski F-Score | 5 |